Author of

• 25970

  +

  P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27756

    +

    P3.16-16 - Long Term Outcomes of Body Gamma-Ray Stereotactic Ablative Radiotherapy for Patients with Stage I/II Non-Small Cell Lung Cancer (ID 13454)

    12:00 - 13:30  |  Author(s): Yingjie Wang
    • Abstract

    Background
    

    The authors evaluated the efficacy, patterns of failure, toxicity and cost of body gamma-ray stereotactic ablative radiotherapy (Body Gamma-ray SABR) for patients with medically inoperable, clinical stage I/II non-small cell lung cancer (NSCLC) with 8 years of follow-up. Clinical staging was performed according to the sixth edition of the American Joint Committee on Cancer TNM staging system.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Eligible patients who had no previous treatments, with histologically confirmed NSCLC, determined as clinical stage I /II, underwent OUR-QGD type of the body gamma-ray SABR (70 grays in 10 fractions for gross target volume) at the Radiation Oncology Department, People's Liberation Army Airforce General Hospital, Beijing, China from January 2007 to July 2010. All patients were immobilized by vacuum bag, and then a slow CT scan was performed without any respiration gating. The total radiation dose of 50%, 60%, and 70% isodose line were prescribed in 50, 60, and 70 Grey (Gy) correspondingly, covering 100% of the planning target volume (PTV), 90% of the clinical target volume (CTV), and 80% of the gross target volume (GTV) in 10 fractions. The CT scan and/or positron emission tomography/computed tomography were every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually thereafter to evaluate the efficacy of the treatment. The primary endpoint was overall survival.

    4c3880bb027f159e801041b1021e88e8 Result
    

    A total of 29 patients were eligible for analysis. The median age of the patients was 71 years (55-87), and the median follow-up was 8.1 years (6.8-10.3). The 1-year, 3-year, 5-year and 8-year overall survival rates were 93.1%, 72.1%, 59.4% and 44.8%, and the local, regional and distant disease recurrence were 10.3%, 13.8% and 13.8% at 5 years and 10.3%, 17.2% and 20.7% at 8 years. Two patients (6.9%) experienced grade 3 treatment-related adverse events. No patients developed grade 4 or 5 adverse events. The median cost of body gamma-ray SABR is 4838 dollars (4615-4923 dollars).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    With long-term follow-up, the results of the current study demonstrated outstanding local control and low toxicity after body gamma-ray SABR in patients with clinical stage I/II NSCLC. The dominant failure included regional and distant disease recurrence. And the body Gamma-ray SABR is pretty cost-effective.

    6f8b794f3246b0c1e1780bb4d4d5dc53